Induction of donor-specific unresponsiveness to cardiac allografts in rats by pretransplant anti-CD4 monoclonal antibody therapy. 1990

J A Shizuru, and K B Seydel, and T F Flavin, and A P Wu, and C C Kong, and E G Hoyt, and N Fujimoto, and M E Billingham, and V A Starnes, and C G Fathman
Department of Medicine, Stanford University Medical Center, California 94305.

In the present report a monoclonal antibody designated OX-38 directed against the rat CD4 molecule was tested for its ability to prolong the survival of heterotopic vascularized rat heart allografts transplanted across major histocompatibility barriers. Fluorescence-activated cell-sorter analysis showed that administration of OX-38 selectively depleted 80-95% of CD4+ cells from peripheral blood of treated rats. The immunosuppressive effects of OX-38 in vivo were verified by suppression of an antibody response against OX-38 itself as a heterologous protein immunogen. Recipient rats received OX-38 antibody as a single agent given in pretransplant regimens. Nine of 12 treated rats have maintained heterotopic abdominal heart allografts for greater than 175 days. Control rats that did not receive antibody therapy rejected their grafts within 14 days. Rats that maintained heart allografts for greater than 100 days accepted second donor strain hearts but rejected third-party heart grafts transplanted into the femoral space. Anti-CD4-induced allograft unresponsiveness persisted for at least 90 days following surgical removal of donor tissue and retransplantation of a second donor-matched heart. These results indicated that transient, pretransplant therapy with monoclonal antibodies directed against the CD4+ lymphocyte induced specific, long-lasting unresponsiveness to fully MHC-mismatched cardiac allografts in rats without additional immunosuppression.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D008212 Lymphocyte Depletion Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation. Depletion, Lymphocyte
D008297 Male Males
D011912 Rats, Inbred ACI An inbred strain of rat that is widely used in BIOMEDICAL RESEARCH. Applications include the study of spontaneous NEOPLASMS; CHRONIC KIDNEY DISEASES, and CONGENITAL ABNORMALITIES. Rats, Inbred A x C 9935 Irish,Rats, ACI,ACI Rat,ACI Rat, Inbred,ACI Rats,ACI Rats, Inbred,Inbred ACI Rat,Inbred ACI Rats,Rat, ACI,Rat, Inbred ACI
D011914 Rats, Inbred BN An inbred strain of rat that is widely used in a variety of research areas such as the study of ASTHMA; CARCINOGENESIS; AGING; and LEUKEMIA. Rats, Inbred Brown Norway,Rats, BN,BN Rat,BN Rat, Inbred,BN Rats,BN Rats, Inbred,Inbred BN Rat,Inbred BN Rats,Rat, BN,Rat, Inbred BN
D011917 Rats, Inbred Lew An inbred strain of rat that is used in BIOMEDICAL RESEARCH. Rats, Inbred Lewis,Rats, Lew,Inbred Lew Rat,Inbred Lew Rats,Inbred Lewis Rats,Lew Rat,Lew Rat, Inbred,Lew Rats,Lew Rats, Inbred,Lewis Rats, Inbred,Rat, Inbred Lew,Rat, Lew
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft
D006649 Histocompatibility Antigens A group of antigens that includes both the major and minor histocompatibility antigens. The former are genetically determined by the major histocompatibility complex. They determine tissue type for transplantation and cause allograft rejections. The latter are systems of allelic alloantigens that can cause weak transplant rejection. Transplantation Antigens,Antigens, Transplantation,Histocompatibility Antigen,LD Antigens,SD Antigens,Antigen, Histocompatibility,Antigens, Histocompatibility,Antigens, LD,Antigens, SD
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal

Related Publications

J A Shizuru, and K B Seydel, and T F Flavin, and A P Wu, and C C Kong, and E G Hoyt, and N Fujimoto, and M E Billingham, and V A Starnes, and C G Fathman
January 1999, Transplantation proceedings,
J A Shizuru, and K B Seydel, and T F Flavin, and A P Wu, and C C Kong, and E G Hoyt, and N Fujimoto, and M E Billingham, and V A Starnes, and C G Fathman
March 1993, Transplantation,
J A Shizuru, and K B Seydel, and T F Flavin, and A P Wu, and C C Kong, and E G Hoyt, and N Fujimoto, and M E Billingham, and V A Starnes, and C G Fathman
January 1994, Transplantation,
J A Shizuru, and K B Seydel, and T F Flavin, and A P Wu, and C C Kong, and E G Hoyt, and N Fujimoto, and M E Billingham, and V A Starnes, and C G Fathman
June 1993, Transplantation,
J A Shizuru, and K B Seydel, and T F Flavin, and A P Wu, and C C Kong, and E G Hoyt, and N Fujimoto, and M E Billingham, and V A Starnes, and C G Fathman
June 1993, Transplantation,
J A Shizuru, and K B Seydel, and T F Flavin, and A P Wu, and C C Kong, and E G Hoyt, and N Fujimoto, and M E Billingham, and V A Starnes, and C G Fathman
March 1998, Transplantation proceedings,
J A Shizuru, and K B Seydel, and T F Flavin, and A P Wu, and C C Kong, and E G Hoyt, and N Fujimoto, and M E Billingham, and V A Starnes, and C G Fathman
June 1992, Transplantation proceedings,
J A Shizuru, and K B Seydel, and T F Flavin, and A P Wu, and C C Kong, and E G Hoyt, and N Fujimoto, and M E Billingham, and V A Starnes, and C G Fathman
November 1993, Transplantation,
J A Shizuru, and K B Seydel, and T F Flavin, and A P Wu, and C C Kong, and E G Hoyt, and N Fujimoto, and M E Billingham, and V A Starnes, and C G Fathman
June 1995, Transplantation proceedings,
J A Shizuru, and K B Seydel, and T F Flavin, and A P Wu, and C C Kong, and E G Hoyt, and N Fujimoto, and M E Billingham, and V A Starnes, and C G Fathman
March 1999, Transplantation,
Copied contents to your clipboard!